Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 121 AL 135

New connections: Amyloid-β, calcium, and the synapse

Ferrarelli LK.

Sci Signal. 2017 Jul 11;10(487):eaao3024. doi: 10.1126/scisignal.aao3024.

Astrocyte: An Innovative Approach for Alzheimer's Disease Therapy

Bronzuoli MR, Facchinetti R, Steardo L, Scuderi C.

Curr Pharm Des. 2017;23(33):4979-4989. doi: 10.2174/1381612823666170710163411.

Targeting Human Astrocytes' Calcium-sensing Receptors for Treatment of Alzheimer's Disease

Chiarini A, Armato U, Whitfield JF, Pra ID.

Curr Pharm Des. 2017;23(33):4990-5000. doi: 10.2174/1381612823666170710162509.

A Brief Review of Three Common Supplements Used in Alzheimer's Disease

Spence J, Chintapenta M, Kwon HI, Blaszczyk AT.

Consult Pharm. 2017 Jul 1;32(7):412-414. doi: 10.4140/TCP.n.2017.412.

Current advances in transdermal delivery of drugs for Alzheimer's disease

Nguyen TT, Giau VV, Vo TK.

Indian J Pharmacol. 2017 Mar-Apr;49(2):145-154. doi: 10.4103/0253-7613.208143.

An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds

Zanforlin E, Zagotto G, Ribaudo G.

Curr Med Chem. 2017 Nov 17;24(34):3749-3773. doi: 10.2174/0929867324666170712161829.

Natural product for the treatment of Alzheimer's disease

Bui TT, Nguyen TH.

J Basic Clin Physiol Pharmacol. 2017 Sep 26;28(5):413-423. doi: 10.1515/jbcpp-2016-0147.

Antagonism of the 5-HT(6) receptor - Preclinical rationale for the treatment of Alzheimer's disease

de Jong IEM, Mørk A.

Neuropharmacology. 2017 Oct;125:50-63. doi: 10.1016/j.neuropharm.2017.07.010. Epub 2017 Jul 12.

Amyloid beta: structure, biology and structure-based therapeutic development

Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE.

Acta Pharmacol Sin. 2017 Sep;38(9):1205-1235. doi: 10.1038/aps.2017.28. Epub 2017 Jul 17.

Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core

Lin H, Li Q, Gu K, Zhu J, Jiang X, Chen Y, Sun H.

Curr Top Med Chem. 2017;17(27):3000-3016. doi: 10.2174/1568026617666170717114944.

Drug candidates in clinical trials for Alzheimer's disease

Hung SY, Fu WM.

J Biomed Sci. 2017 Jul 19;24(1):47. doi: 10.1186/s12929-017-0355-7.

Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease

Lee JK, Kim NJ.

Molecules. 2017 Aug 2;22(8):1287. doi: 10.3390/molecules22081287.

MicroRNA Dysregulation in Alzheimer's Disease

Putteeraj M, Fairuz YM, Teoh SL.

CNS Neurol Disord Drug Targets. 2017;16(9):1000-1009. doi: 10.2174/1871527316666170807142311.

Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target

Wang Y, Yan T, Lu H, Yin W, Lin B, Fan W, Zhang X, Fernandez-Funez P.

Neurodegener Dis. 2017;17(6):242-250. doi: 10.1159/000478741. Epub 2017 Aug 9.

Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents

Jouanne M, Rault S, Voisin-Chiret AS.

Eur J Med Chem. 2017 Oct 20;139:153-167. doi: 10.1016/j.ejmech.2017.07.070. Epub 2017 Jul 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias